GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » Net Current Asset Value

Zhaoke Ophthalmology (HKSE:06622) Net Current Asset Value : HK$2.85 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Zhaoke Ophthalmology's net current asset value per share for the quarter that ended in Dec. 2023 was HK$2.85.

The historical rank and industry rank for Zhaoke Ophthalmology's Net Current Asset Value or its related term are showing as below:

HKSE:06622' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.53   Med: 1.2   Max: 1.39
Current: 0.53

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Zhaoke Ophthalmology was 1.39. The lowest was 0.53. And the median was 1.20.

HKSE:06622's Price-to-Net-Current-Asset-Value is ranked better than
95.72% of 1027 companies
in the Biotechnology industry
Industry Median: 3.93 vs HKSE:06622: 0.53

Zhaoke Ophthalmology Net Current Asset Value Historical Data

The historical data trend for Zhaoke Ophthalmology's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhaoke Ophthalmology Net Current Asset Value Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
-0.42 -2.35 4.74 3.59 2.85

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only 4.74 4.12 3.59 3.29 2.85

Competitive Comparison of Zhaoke Ophthalmology's Net Current Asset Value

For the Biotechnology subindustry, Zhaoke Ophthalmology's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhaoke Ophthalmology's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Zhaoke Ophthalmology's Price-to-Net-Current-Asset-Value falls into.



Zhaoke Ophthalmology Net Current Asset Value Calculation

Zhaoke Ophthalmology's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1962.862-406.908-0-0)/546.139
=2.85

Zhaoke Ophthalmology's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1962.862-406.908-0-0)/546.139
=2.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhaoke Ophthalmology  (HKSE:06622) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Zhaoke Ophthalmology Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhaoke Ophthalmology (HKSE:06622) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.
Executives
Mak Siu Hang Viola 2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd 2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd 2101 Beneficial owner
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Fidelity China Special Situations Plc 2101 Beneficial owner
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Vms Holdings Limited 2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited 2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p. 2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p. 2201 Interest of corporation controlled by you

Zhaoke Ophthalmology (HKSE:06622) Headlines

No Headlines